Skip to content
ResearchEBS

EBS: FY25 Deep Dive

Ddrillr ResearchOriginal research
Published 1 min read

Summary

Emergent BioSolutions FY25 at $743M. NI $53M; EPS $0.93.

FY25 revenue $743M; OI $110M; NI $53M; EPS $0.93.

Emergent BioSolutions FY25 (Dec 31, 2025) at $743M revenue. OpInc $110M; NI $53M; EPS $0.93. Pharma — Biodefense.